Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: Testing positive/ Twenty-five days later (on 17-May-2022), I began feeling ill and again tested positive for covid/malaise; Interchange of vaccine products; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Testing positive/ Twenty-five days later (on 17-May-2022), I began feeling ill and again tested positive for covid/malaise) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. O48F21A) for COVID-19 vaccination.     Previously administered products included for Drug use for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (Dose Number: 2 Batch/Lot No: EP7534 Location of injection: Arm Left) on 20-Mar-2021. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE. Concurrent medical conditions included Asthma and Allergy to antibiotic (Keflex). Concomitant products included DROSPIRENONE, ETHINYLESTRADIOL BETADEX CLATHRATE (YAZ) and SPIRONOLACTONE for an unknown indication.    On 06-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Nov-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). On 17-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (Testing positive/ Twenty-five days later (on 17-May-2022), I began feeling ill and again tested positive for covid/malaise). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 17-Apr-2022 to 22-Apr-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Testing positive/ Twenty-five days later (on 17-May-2022), I began feeling ill and again tested positive for covid/malaise) had not resolved and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Apr-2022, SARS-CoV-2 test: positive (Positive) Positive. On 17-May-2022, SARS-CoV-2 test: positive (Positive) Positive.         The patient had taken other medications/products within 2 weeks of starting COVID-19 treatment.  Patient had previously received a COVID-19 Vaccine.  It was reported that day after the patient finished a full course of Paxlovid, (6 days after testing positive), the patient tested Negative and exited isolation and resumed normal activities.  Twenty-five days later which was on 17-May-2022, the patient began feeling ill and again tested positive for covid.   For treatment another course of Paxlovid has been prescribed  Company comment: This is a spontaneous case concerning a 34-year-old, female patient with no relevant medical history and with vaccine history of receiving Covid-19 BioNTech as the second dose, who experienced the unexpected non-serious AESI event of Covid-19. Interchange of vaccine products was also reported. The event occurred approximately 192 days after the third dose of mRNA-1273 vaccine administration in Covid-19 vaccination in series. The event was described as recurrence of Covid-19 after treatment with Nirmatrelvir (Paxlovid). Allegedly the day after the patient finished a full course of Paxlovid, (6 days after testing positive) patient was tested negative. Patient exited isolation and resumed normal activities. Twenty-five days later, patient began feeling ill and again tested positive for Covid-19. No other information surrounding the event was reported. The outcome of the event was reported as not resolved. The current Covid-19 pandemic remain confounder for the event Covid-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 34-year-old, female patient with no relevant medical history and with vaccine history of receiving Covid-19 BioNTech as the second dose, who experienced the unexpected non-serious AESI event of Covid-19. Interchange of vaccine products was also reported. The event occurred approximately 192 days after the third dose of mRNA-1273 vaccine administration in Covid-19 vaccination in series. The event was described as recurrence of Covid-19 after treatment with Nirmatrelvir (Paxlovid). Allegedly the day after the patient finished a full course of Paxlovid, (6 days after testing positive) patient was tested negative. Patient exited isolation and resumed normal activities. Twenty-five days later, patient began feeling ill and again tested positive for Covid-19. No other information surrounding the event was reported. The outcome of the event was reported as not resolved. The current Covid-19 pandemic remain confounder for the event Covid-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.